Rabbit Recombinant Monoclonal SIGLEC6 antibody. Carrier free. Suitable for Flow Cyt and reacts with Transfected cell line - Human, Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Flow Cyt | WB | IHC-P | ICC/IF | IP | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Transfected cell line - Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Transfected cell line - Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Transfected cell line - Human, Mouse, Rat | Dilution info - | Notes - |
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.
CD327, CD33L, CD33L1, OBBP1, SIGLEC6, Sialic acid-binding Ig-like lectin 6, Siglec-6, CD33 antigen-like 1, CDw327, Obesity-binding protein 1, OB-BP1
Rabbit Recombinant Monoclonal SIGLEC6 antibody. Carrier free. Suitable for Flow Cyt and reacts with Transfected cell line - Human, Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab317310 is the carrier-free version of Anti-SIGLEC6 antibody [EPR28608-365] ab317309.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
SIGLEC6 also known as CD327 is a protein found on some immune cells particularly on B cells and to a lesser extent on macrophages and dendritic cells. This protein has a molecular mass of around 100 kDa. As a member of the sialic acid-binding immunoglobulin-type lectins family (siglecs) SIGLEC6 mechanistically functions by recognizing and binding to specific sialic acid-containing carbohydrates on cell surfaces. This recognition influences cell-cell interactions and signaling processes important for immune response modulation.
Four words that are not SIGLEC6 illustrate its involvement in immune system regulation. SIGLEC6 serves as an inhibitory receptor that helps dampen B cell receptor signaling balancing the immune response to prevent overactivation. It often partners with other proteins in complex cellular interactions within the immune cells. The expression of SIGLEC6 in placental tissues also suggests a role in trophoblast invasion and development although this function requires more research to fully understand the mechanisms involved.
Four words that are not SIGLEC6 describe its integration into the immune signaling pathways particularly the immune response regulation. SIGLEC6 is a part of the B cell receptor signaling pathway acting as an inhibitory modulator. Through this pathway it connects with proteins like CD22 and other siglecs that contribute to the regulation of B cell activity. Additionally its role in glycan recognition links it to pathways associated with cell surface interactions and immune tolerance.
Four words that are not SIGLEC6 highlight its relevance to certain conditions. SIGLEC6 expression alterations have implications in chronic lymphocytic leukemia (CLL) where it potentially influences disease progression by modulating B cell signaling. The protein has also been connected to gestational trophoblastic diseases potentially affecting placental development. In these contexts SIGLEC6 interacts with proteins such as CD22 in CLL where they collectively affect leukemic cell behaviors and disease outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-SIGLEC6 antibody [EPR28608-365] ab317309, the same antibody clone in a different buffer formulation.
Flow cytometric analysis of Isotype (Left) / 293T cells transfected with a SIGLEC6 expression vector containing a GFP-tag (Middle) /293T cells transfected an empty vector containing a GFP-tag (Right) cells labelling SIGLEC6 with Anti-SIGLEC6 antibody [EPR28608-365] ab317309 at 1/5000 dilution (0.01ug) / Middle and Right compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control.
Goat anti-Rabbit IgG (Alexa Fluor® 647, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) preadsorbed ab150083) at 1/5000 dilution was used as the secondary antibody.
Gated on viable cells.
This data was developed using Anti-SIGLEC6 antibody [EPR28608-365] ab317309, the same antibody clone in a different buffer formulation.
Flow cytometric analysis of Human PBMC(human peripheral blood mononuclear cell) cells labelling SIGLEC6 with Anti-SIGLEC6 antibody [EPR28608-365] ab317309 at 1/50 dilution (1ug)/Right compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control.
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Cells were co-stained with anti-CD19 conjugated to Alexa Fluor®647.
Gated on viable cells.
This data was developed using Anti-SIGLEC6 antibody [EPR28608-365] ab317309, the same antibody clone in a different buffer formulation.
Flow cytometric analysis of Human PBMC(human peripheral blood mononuclear cell) cells labelling SIGLEC6 with Anti-SIGLEC6 antibody [EPR28608-365] ab317309 at 1/50 dilution (1ug)/Right compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Left isotype control.
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Cells were co-stained with anti-CD3 conjugated to Brilliant Violet 421.
Gated on viable cells.
This data was developed using Anti-SIGLEC6 antibody [EPR28608-365] ab317309, the same antibody clone in a different buffer formulation.
Flow cytometric analysis of U-937 (human histiocytic lymphoma monocyte) (Right) / HepG2 (human hepatocellular carcinoma epithelial cell) (Left) cells labelling SIGLEC6 with Anti-SIGLEC6 antibody [EPR28608-365] ab317309 at 1/50 dilution (1ug)/Red compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Low expression: HepG2.
Gated on viable cells.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com